Most businesses earn when a customer pays at the point of sale. Community pharmacy works differently. The dominant income stream does not come from the shop till at all: it comes from the NHS, paid weeks after the dispensing took place, at prices set not by the pharmacy but by central government. Understanding this structure is the starting point for anyone who owns, buys, or is thinking about acquiring a pharmacy.
Note: The NHS contract arrangements described here apply in England. Scotland, Wales and Northern Ireland operate under separate contractual frameworks, though Wales uses the same Drug Tariff.
How pharmacies make money, in one paragraph
A community pharmacy in England earns mainly through the NHS Community Pharmacy Contractual Framework (CPCF): reimbursement for the drugs it dispenses at Drug Tariff prices, plus remuneration in the form of dispensing fees and service payments. A smaller layer of over-the-counter retail and private-service income sits alongside. The income is contract-driven, not till-driven: the NHS contract, and the volume of prescriptions it generates, is the business. The shop is the delivery vehicle.
The NHS contract is the engine
Every NHS prescription dispensed by a community pharmacy in England generates a claim under the CPCF. That claim has two components: reimbursement and remuneration.
Reimbursement covers the cost of the drugs themselves. NHSBSA prices each item against the Drug Tariff and pays back what it calculates the pharmacy is owed. The pharmacy does not set these prices.
Remuneration covers the fees for providing the dispensing service: in England, a single activity fee on every item, plus service payments such as Pharmacy First. These are also centrally determined and published.
So how much is it worth? For 2026/27, the settlement agreed by DHSC, NHS England and Community Pharmacy England (their joint letter of 29 May 2026) puts total contract funding at £3.636 billion across England, £340 million more than 2025/26, with Pharmacy First now inside it (CPCF 2026/27 letter). The single activity fee on each item goes from £1.46 to £1.52, backdated to May 2026, while other service fees stay at 2025/26 levels. Retained medicine margin, the buying margin on drugs the contract lets the sector keep, is set at £1.1 billion. A Pharmacy First clinical pathway consultation pays £17, plus a monthly fixed payment once consultations reach 20 (£500 for 20 to 29, £1,000 from 30). Which of those earns your pharmacy the most comes down to your item numbers and how many consultations you do, and your FP34 schedules show it line by line.
Both components are claimed through the FP34 monthly submission to NHSBSA. The NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013 govern who can hold an NHS contract and on what terms. Entry is regulated: you cannot simply open a pharmacy and join the NHS payment system without meeting the regulatory criteria. This is why the NHS contract, not the premises, is the dominant asset when a pharmacy changes hands.
Reimbursement versus remuneration: the two halves of NHS income
The distinction matters for management accounts and for valuation.
| Income component | What it covers | Who sets it | Accounting note |
|---|---|---|---|
| Drug reimbursement | Cost of drugs dispensed, priced against the Drug Tariff and Category M list prices | DHSC sets the prices in the Drug Tariff; NHSBSA prices each claim and pays | Zero-rated for VAT; gross margin is not controlled by the pharmacy and moves when Category M prices change each quarter |
| Dispensing fees | Per-item and per-prescription fees for the dispensing service | DHSC, NHS England and Community Pharmacy England (CPCF settlement) | Part of remuneration; flows through FP34 alongside reimbursement |
| Service payments | Pharmacy First and other commissioned services | NHS England | Separately accounted; own fee structure and activity thresholds |
| OTC and private retail | Medicines and products sold without a prescription; private consultations and services | The pharmacy (market-priced) | Standard-rated for VAT (generally); different margin economics from dispensing |
The critical point on reimbursement is that Drug Tariff prices are set centrally, before you dispense, and DHSC changes Category M prices each quarter so the sector as a whole keeps the margin the contract funds. Nothing you've dispensed is repriced afterwards. A pharmacy can't negotiate its reimbursement price or sell its way to a better one. The selling side of the margin is what the system sets it to be; the side you can work on is what you pay your wholesalers. This is why Category M clawbacks and Drug Tariff changes are a recurring management-accounts event, not a one-off. It is also why benchmarking your actual margin against sector norms is a more useful exercise than trying to manage the reimbursement rate itself. See pharmacy margin benchmarking for how that analysis works in practice.
Service income: the growing line
Pharmacy First is the most visible current example of NHS-commissioned service income: a programme through which community pharmacies provide clinical consultations for a defined set of conditions, reducing pressure on GP surgeries. Its budget used to sit outside the contract; from 2026/27 it's merged into the CPCF. It carries its own fee structure and activity thresholds, and it is accounted for separately from core dispensing reimbursement.
For management-accounts and valuation purposes, service income is worth tracking as a distinct line. It reflects active delivery of commissioned services rather than volume of prescriptions processed, and it is the area where policy change is most likely to shift the income mix over the coming years.
Pharmacy First's 2026/27 rates come from that year's settlement, and fee schedules can change with each one, so check the current rates on the NHS England Pharmacy First pages before relying on them. See also how Pharmacy First income is accounted for for the practical bookkeeping treatment.
The retail and OTC layer, and why it is different
Community pharmacies also sell over-the-counter medicines and related products alongside their NHS dispensing. This retail income is market-priced and the pharmacy can influence its margin directly, unlike reimbursement. However, the economics carry a structural difference that does not apply to a normal shop.
NHS-dispensed prescription drugs are zero-rated for VAT, while HMRC calls medicines sold over the counter "a separate, standard-rated supply", at 20%. A pharmacy is structurally a VAT-mixed business. The zero-rated dispensing volume means that input VAT on costs related to that activity is reclaimable, which changes the effective cost base compared with a pure retailer. Getting the VAT split right, using an appropriate retail scheme to apportion mixed sales, matters materially at pharmacy scale.
The OTC retail layer also does not replace the NHS contract as the core earnings driver. For a dispensing pharmacy, it's the dispensing volume and the NHS fees attached to it that determine the business's value. See how VAT works in a pharmacy for the detail on the zero-rated and standard-rated mix.
Why the till does not tell you the profit
Two features of NHS income mean that cash in the bank and income earned are always out of step in a community pharmacy.
First, the timing. Prescriptions dispensed in a given month are submitted to NHSBSA the following month via the FP34 process. Declare by the 5th and NHSBSA advances 100% of its estimate around the 10th of that month, settling the difference two months or so after you submit. So you wait a few weeks for the advance, not two months, but the month's stock and wages go out before the advance lands, and the final figure isn't settled until the reconciliation. At any point in time, a pharmacy has NHS income in transit between dispensing and settlement. The FP34 payment cycle explains the mechanics in full, and the FP34 cash-flow estimator lets you model the lag against your own dispensing volume.
Second, the price. The amount NHSBSA settles is based on centrally set Drug Tariff prices. The advance is an estimate built on your average item value, so when the month's items are actually priced, the reconciliation can land above or below it, and Category M prices that changed at the start of a quarter make that more likely. Reconciling the settlement against the FP34 submission is a routine but load-bearing monthly task, not an optional check. See Drug Tariff changes explained and Category M clawbacks explained for the mechanics of each.
Enter a month's items, average item value and costs to see when NHSBSA's advance and reconciliation land and the cash you need before the first payment arrives.
NHS FP34 Cash Flow Estimator
You don't get paid for NHS dispensing at the counter. You submit the month's prescriptions to NHSBSA by the 5th of the next month, it pays an estimated 100% advance around the 10th, and it settles the difference about two months after you submit. Put in your own figures to see when the money lands and how much you need for stock and wages before it does.
The number of items on the month's FP34 submission.
NHSBSA's monthly average item value, fees and drug cost (net ingredient cost) together, as shown on your FP34 Schedule of Payment. £10 is only an example, so use your own.
NHSBSA takes these off what it pays you, because you've already collected them at the counter. £1,000 is an example.
NHSBSA publishes a latest date each month to guarantee the advance (in 2026, between the 19th and the 24th). Miss it and there's no advance: you're paid with the reconciliation.
What leaves your account during the month you're dispensing, apart from the wholesaler. £5,000 is an example.
What your wholesaler invoices for the medicines you dispensed that month. £13,000 is an example.
When your wholesaler takes payment, counted from the last day of the month you dispensed. Check your own terms; 20 days is an example.
The advance uses NHSBSA's average item value. If the month's items turn out to be worth more, the reconciliation pays you the difference; if they're worth less, NHSBSA takes it back from a later advance.
Your result
Your answer's ready. Press below to see it.
What this means if you own or are buying a pharmacy
Because income is contract-driven rather than retail-driven, the core financial discipline in a community pharmacy is different from a shop's. Margin is not set by the owner, so the levers are volume, overhead control, service income development, and working-capital management around the FP34 lag. Profit improvement comes from operational efficiency and service income growth, not from repricing the dispensing line.
For buyers, the implication is that what you are acquiring is principally the NHS contract, the volume of prescriptions it attracts, and the history of margin that goes with it. Goodwill is the part of the price that pays for that contract volume and item count, over and above the stock and fittings. The Pharmacy Openings and Closures Index tracks the structural changes in supply across England and provides context for how contract availability and consolidation dynamics are moving at a market level. If you are evaluating a specific acquisition, the pharmacy buyer's checklist, the finance mechanics for first-time buyers, and the worked investment figures all build on this revenue-model foundation.
For owners, the monthly accounting workflow sits on top of this same structure: FP34 reconciliation, Category M variance tracking, service-income reporting, and payroll cost management are the recurring tasks that determine whether the business's profit matches its dispensing activity. If you want to understand how your pharmacy's margin compares with the sector, our benchmarking and margin review is the service that surfaces that data.
The buying a pharmacy hub covers the acquisition journey end to end, and pharmacy owners covers the ongoing finance and tax picture.
Want this checked against your specific situation?
Leave your details and a one-line summary. One of our specialists will come back to you, with no obligation.